A review of the effects of statins in systemic sclerosis

Kuwana, 2006, Potential benefits of statins for vascular disease in systemic sclerosis, Curr Opin Rheum, 18, 594, 10.1097/01.bor.0000245720.02512.3e Muller-Ladner, 2009, Mechanisms of vascular damage in systemic sclerosis, Autoimmunity, 42, 587, 10.1080/08916930903002487 Abraham, 2009, Overview of pathogenesis of systemic sclerosis, Rheumatology, 48, iii3 Rossi, 2008, Prognostic role of flow-mediated dilation and cardiac risk factors in post-menopausal women, J Am Coll Cardiol, 51, 997, 10.1016/j.jacc.2007.11.044 Au, 2012, Atherosclerosis in systemic sclerosis–a systematic review and meta-analysis, Arthritis Rheum, 63, 2078, 10.1002/art.30380 Bellosta, 2004, Safety of statins: focus on clinical pharmacokinetics and drug interactions, Circulation, 109, III50 Chakrabarti, 1991, Interrelationships between mevalonate metabolism and the mitogenic signaling pathway in T lymphocyte proliferation, J Biol Chem, 266, 12216, 10.1016/S0021-9258(18)98884-8 Azuma, 2004, HMG-CoA reductase inhibitor attenuates experimental autoimmune myocarditis through inhibition of T cell activation, Cardiovasc Res, 64, 412, 10.1016/j.cardiores.2004.09.014 Yilmaz, 2004, HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis, Atherosclerosis, 172, 85, 10.1016/j.atherosclerosis.2003.10.002 Greenwood, 2006, Statin therapy is autoimmunity: from protein prenylation to immunomodulation, Nat Rev Immunol, 6, 5, 10.1038/nri1839 Kwak, 2000, Statins as a newly recognised type of immunomodulator, Nat Med, 6, 1399, 10.1038/82219 Zhang, 2008, Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes, J Immunol, 180, 6988, 10.4049/jimmunol.180.10.6988 Nath, 2004, Potential targets of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor for multiple sclerosis therapy, J Immunol, 172, 1273, 10.4049/jimmunol.172.2.1273 Khattri, 2013, Statins and autoimmunity, Immunol Res, 56, 348, 10.1007/s12026-013-8409-8 Ngian, 2011, Cardiovascular disease in systemic sclerosis—an emerging association?, Arthritis Res Ther, 13, 237, 10.1186/ar3445 Chu, 2013, Increased risk of acute myocardial infarction in systemic sclerosis: a nationwide population-based study, Am J Med, 126, 982, 10.1016/j.amjmed.2013.06.025 Ota, 2011, Atorvastatin attenuates skin fibrosis through the PI3K pathway, Arthritis Rheum, 63, S905 Del Papa, 2001, Influence of atorvastatin on normal and scleroderma fibroblast activation and type 1 collagen production, Arthritis Rheum, 44 Louneva, 2006, Inhibition of systemic sclerosis dermal fibroblast type I collagen production and gene expression by simvastatin, Arthritis Rheum, 54, 1298, 10.1002/art.21723 Bagnato, 2013, Simvastatin attenuates the development of pulmonary and cutaneous fibrosis in a murine model of systemic sclerosis, Rheumatology, 52, 1377, 10.1093/rheumatology/ket144 Bagnato, 2014, Simvastatin modulates aortic intima/media thickness in an animal model of systemic sclerosis, Clin Exp Rheumatol, 32 Alekperov, 2010, Endothelial dysfunction and inflammation markers dynamics during atorvastatin treatment in systemic sclerosis, Clin Exp Rheumatol, 28, S167 Abou-Raya, 2008, Statins: potentially useful in therapy of systemic sclerosis-related Raynaud’s phenomenon and digital ulcers, J Rheumatol, 35, 1801 Del Papa, 2008, Simvastatin reduces endothelial activation and damage but is partially ineffective in inducing endothelial 867 repair in systemic sclerosis, J Rheumatol, 35, 1323 Yatsyshyn, 2012, Clinical efficiency of rosuvastatin in patients with systemic scleroderma, Rheumatology, 51 Kuwana, 2009, Long-term beneficial effects of statins on vascular manifestations in patients with systemic sclerosis, Mod Rheumatol, 19, 530, 10.3109/s10165-009-0199-4 Rossi, 2012, Increased finger skin vasoreactivity and stimulated vasomotion associated with simvastatin therapy in systemic sclerosis hypercholesterolemic patients, Rheumatol Int, 32, 3715, 10.1007/s00296-011-2183-5 Timar, 2013, Rosuvastatin improves impaired endothelial function, lowers high sensitivity CRP, complement and immuncomplex production in patients with systemic sclerosis—a prospective case-series study, Arthritis Res Ther, 15, R105, 10.1186/ar4285 Furukawa, 2006, Protective effect of pravastatin on vascular endothelium in patients with systemic sclerosis: a pilot study, Ann Rheum Dis, 65, 1118, 10.1136/ard.2005.046870 Sadik, 2010, Lack of effect of 8 weeks atorvastatin on microvascular endothelial function in patients with systemic sclerosis, Rheumatology, 49, 990, 10.1093/rheumatology/keq003 Ionitescu, 2010, Simvastatin in systemic sclerosis patients—an open-label study, Clin Exp Rheumatol, 28, S158 Kuwana, 2006, Increase in circulating endothelial precursors by atorvastatin in patients with systemic sclerosis, Arthritis Rheum, 54, 1946, 10.1002/art.21899 Bazzichi, 2007, Short therapy with simvastatin improves endothelial function in patients affected by systemic sclerosis, Ann Rheum Dis, 66, 200 Beretta, 2006, Twelve-weeks therapy with fluvastatin improves brachial arterial endothelium-dependent vasodilation in patients with systemic sclerosis, Ann Rheum Dis, 65, 384 Pope, 2011, Arthritis Care Res, 63, S98, 10.1002/acr.20598 Muangchan, 2013, The significance of interleukin-6 and C-reactive protein in systemic sclerosis: a systematic literature review, Clin Exp Rheumatol, 31, S122 Derk, 2006, Inhibition of geranyl-geranyl prenylation by statins: a novel model of disease modification of systemic sclerosis, Letters Drug Des Discov, 3, 183, 10.2174/157018006776286998 Batteux, 2011, New insights on chemically induced animal models of systemic sclerosis, Curr Opin Rheumatol, 23, 511, 10.1097/BOR.0b013e32834b1606 Derk, 2005, Statins and the vasculopathy of systemic sclerosis: potential therapeutic agents?, Autoimmun Rev, 5, 25, 10.1016/j.autrev.2005.06.010 Distler, 2004, Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis, Circ Res, 95, 109, 10.1161/01.RES.0000134644.89917.96 Distler, 2002, Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers, Arthritis Res, 4, R11, 10.1186/ar596 Distler, 2009, EULAR Scleroderma Trials and Research group statement and recommendations on endothelial precursor cells, Ann Rheum Dis, 68, 163, 10.1136/ard.2008.091918 Del Papa, 2006, Bone marrow endothelial progenitors are defective in systemic sclerosis, Arthritis Rheum, 54, 2605, 10.1002/art.22035 Del Papa, 2010, Antiendothelial cell antibodies induce apoptosis of bone marrow endothelial progenitors in systemic sclerosis, J Rheum, 37, 2053, 10.3899/jrheum.091346 Vasa, 2001, Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease, Circ Res, 89, E1, 10.1161/hh1301.093953 Llevadot, 2001, HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells, J Clin Invest, 108, 399, 10.1172/JCI200113131 Vasa, 2001, Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease, Circulation, 103, 2885, 10.1161/hc2401.092816 Assmus, 2003, HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes, Circ Res, 92, 1049, 10.1161/01.RES.0000070067.64040.7C Charakida, 2010, Assessment of atherosclerosis: the role of flow-mediated dilatation, Eur Heart J, 31, 2854, 10.1093/eurheartj/ehq340 Rollando, 2010, Brachial artery endothelial-dependent flow-mediated dilation identifies early-stage endothelial dysfunction in systemic sclerosis and correlates with nailfold microvascular impairment, J Rheumatol, 37, 1168, 10.3899/jrheum.091116 Iwata, 2012, Inhibitory effect of statins on inflammatory cytokine production from human bronchial epithelial cells, Clin Exp Immunol, 168, 234, 10.1111/j.1365-2249.2012.04564.x Ascer, 2004, Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients, Atherosclerosis, 177, 161, 10.1016/j.atherosclerosis.2004.07.003 van de Ree, 2003, Strong decrease of high sensitivity C-reactive protein with highdose atorvastatin in patients with type 2 diabetes mellitus, Atherosclerosis, 166, 129, 10.1016/S0021-9150(02)00316-7 Laufs, 1997, Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase, J Biol Chem, 272, 31725, 10.1074/jbc.272.50.31725 Mueck, 2001, Further evidence for direct vascular actions of statins: effect on endothelial nitric oxide synthase and adhesion molecules, Exp Clin Endocrinol Diabetes, 109, 181, 10.1055/s-2001-14843 Porter, 2004, Simvastatin reduces atrial myofibroblast proliferation independent of cholesterol lowering via inhibition of RhoA, Cardio Res, 61, 745, 10.1016/j.cardiores.2003.11.032 Connor, 2006, Inhibition of protein geranylgeranylation induces apoptosis in synovial fibroblasts, Arthritis Res Ther, 8, R94, 10.1186/ar1968 Cheema, 2006, Abstract 4145: effects of statin and niacin therapy on flow mediated dilation and high sensitivity C-reactive protein in patients with the metabolic syndrome, Circulation, 114 Frick, 2002, Short- and long-term changes of flow-mediated vasodilation in patients under statin therapy, Clin Cardiol, 25, 291, 10.1002/clc.4960250610 Han, 2014, Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease, J Am Coll Cardiol, 63, 62, 10.1016/j.jacc.2013.09.017 Leoncini, 2014, J Am Coll Cardiol, 63, 71, 10.1016/j.jacc.2013.04.105 Purvesh Khatri, 2013, A common rejection module (CRM) for acute rejection across multiple organs identifies novel therapeutics for organ transplantation, JEM Chataway, 2014, Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial, Lancet, 383, 2213, 10.1016/S0140-6736(13)62242-4 Chopra, 2012, Is statin use associated with reduced mortality after pneumonia? A systematic review and meta-analysis, Am J Med, 125, 1111, 10.1016/j.amjmed.2012.04.011 Mortensen, 2012, Population-based study of statins, angiotensin II receptor blockers, and angiotensin-converting enzyme inhibitors on pneumonia-related outcomes, Clin Infect Dis, 55, 1466, 10.1093/cid/cis733 Personal correspondence from Dr. Murray Baron, director of the Canadian Scleroderma Research Group. [accessed 17.06.15].